A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study - Loibl, Sibylle; Untch, Michael; Schneeweiss, Andreas (Annals of oncology, 2019)
Gesehen am 09.01.2020